Merck’s Keytruda Nabs More US Approvals

04:00 EDT 18 Jun 2018 | CHEManager

The US Food and Drug Administration (FDA) has granted two more approvals for US Merck’s Keytruda, an anti-PD-1 therapy. In the first, the drug gained its first regulatory clearance as a gynaecological cancer treatment. It is the first anti-PD-1 therapy to be approved for patients with advanced cervical cancer and progression on or after chemotherapy.

Original Article: Merck’s Keytruda Nabs More US Approvals


More From BioPortfolio on "Merck’s Keytruda Nabs More US Approvals"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...